ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1705

The Risk of Fracture Among Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis

Lauren Harter1, Daniel Shin2, Joshua F. Baker3, Junko Takeshita2, Thorvardur Love4,5, Joel Gelfand6 and Alexis Ogdie7, 1Medicine, University of Pittsburgh, Pittsburgh, PA, 2University of Pennsylvania, Philadelphia, PA, 3Rheumatology, University of Pennsylvania, Philadelphia, PA, 4Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 5Landspitali University Hospital, Reykjavík, Iceland, 6University of Pennsylvania Health System , Philadelphia, PA, 7Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Epidemiologic methods, Fracture risk, psoriasis, psoriatic arthritis and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: While rheumatoid arthritis (RA) has been linked to an increased incidence of osteoporosis (OP) and fracture, few studies have examined the risk of fracture associated with psoriasis and psoriatic arthritis (PsA).  In this study, we determined the risk of fracture among patients with PsA, psoriasis and RA compared with the general population.

Methods: A longitudinal cohort study was conducted in The Health Improvement Network (THIN), a primary care medical record database in the United Kingdom, to determine the risk of fracture (all, hip, and vertebral) using data from 1994-2014. Patients aged 18-89 with a diagnosis of PsA, RA, or psoriasis were selected. Diagnosis codes for PsA, RA, and psoriasis have been validated in THIN. Up to 5 unexposed controls matched on practice and start date within the practice were selected for each exposed patient. Cox proportional hazards models were used to calculate the adjusted hazard ratios (aHR) for each outcome. Multivariable models were constructed to include known risk factors and potential confounders (p-value<0.05 and changed the main effects by >10%).

Results: Patients with PsA (N=9,788), RA (N=39,306), psoriasis (N=158,323) and unexposed controls (N=821,834) were identified. Patients with RA had a significantly elevated risk of fracture: all, hip, and vertebral aHR: 1.23 (1.18-1.28), 1.55 (1.40-1.72), 1.53 (1.30-1.80) respectively. Those with mild psoriasis had significantly elevated risk of all fractures and hip fracture: aHR 1.07 (1.05-1.10) and 1.13 (1.04-1.22). Patients with severe psoriasis had significantly elevated risk of all fracture and vertebral fracture: aHR 1.26 (1.15-1.39) and 2.23 (1.03-1.33). Patients with PsA had a significantly elevated risk of all fracture: aHR 1.26 (1.06-1.27). Patients with PsA had an elevated aHR for hip fracture (1.17; 0.86-1.59), however, this was not statistically significant. These results were robust to several sensitivity analyses.

Conclusion: Patients with PsA, severe psoriasis and RA have an elevated risk for fracture. These results underscore the importance of screening for osteoporosis among patients with these inflammatory conditions.


Disclosure: L. Harter, None; D. Shin, None; J. F. Baker, None; J. Takeshita, Pfizer Inc, 2; T. Love, None; J. Gelfand, Abbvie, Astrazeneca, Celgene Corp, Coherus, Eli Lilly, Janssen Biologics (formerly Centocor), Sanofi, Merck, Novartis Corp, Endo, Valeant, and Pfizer Inc, 5,bbvie, Amgen, Eli Lilly, Janssen, Novartis Corp, Regeneron, and Pfizer Inc, 2; A. Ogdie, Pfizer Inc, 2,Novartis Pharmaceutical Corporation, 5,Abbvie, Celgene, Pfizer, 2.

To cite this abstract in AMA style:

Harter L, Shin D, Baker JF, Takeshita J, Love T, Gelfand J, Ogdie A. The Risk of Fracture Among Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/the-risk-of-fracture-among-patients-with-psoriasis-psoriatic-arthritis-and-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-risk-of-fracture-among-patients-with-psoriasis-psoriatic-arthritis-and-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology